Literature DB >> 24825559

Systemic bevacizumab for simultaneous treatment of cancer and choroidal neovascularisation.

Norman Saffra1, Benjamin Reinherz2.   

Abstract

A 47-year-old woman with a medical history of pseudoxanthoma elasticum and associated choroidal neovascularisation that was successfully managed with intravitreal bevacizumab injections developed non-squamous non-small cell lung carcinoma. The patient's oncological medication regimen included systemic bevacizumab. During the 22 months that the patient received systemic bevacizumab for management of her malignancy, intravitreal bevacizumab injections were held and the patient's visual acuity remained stable and the subretinal space was free of fluid leakage. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24825559      PMCID： PMC4025441          DOI： 10.1136/bcr-2014-204500

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  6 in total

Review 1.  Pseudoxanthoma elasticum: genetics, clinical manifestations and therapeutic approaches.

Authors:  Robert P Finger; Peter Charbel Issa; Markus S Ladewig; Christian Götting; Christina Szliska; Hendrik P N Scholl; Frank G Holz
Journal:  Surv Ophthalmol       Date:  2009 Mar-Apr       Impact factor: 6.048

2.  Long-term effectiveness of intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum.

Authors:  Robert P Finger; Peter Charbel Issa; Steffen Schmitz-Valckenberg; Frank G Holz; Hendrik N Scholl
Journal:  Retina       Date:  2011 Jul-Aug       Impact factor: 4.256

3.  Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study.

Authors:  Andrew A Moshfeghi; Philip J Rosenfeld; Carmen A Puliafito; Stephan Michels; Erin N Marcus; Joshua D Lenchus; Anna S Venkatraman
Journal:  Ophthalmology       Date:  2006-10-05       Impact factor: 12.079

4.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

5.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors:  Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

Review 6.  The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.

Authors:  Cesare Gridelli; Paolo Maione; Antonio Rossi; Filippo De Marinis
Journal:  Oncologist       Date:  2007-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.